Cayce Denton

Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA.

PatientSafe Solutions, Inc. provides wireless workflow optimization and patient safety solutions. It designs hardware and software solutions to provide patient safety and improve patient, family, and nurse satisfaction in hospitals. It offers clinical communications and workflows, coordinated care, and professional services. The company was founded by Keith Blei, Gerald E. Forth, David D. Swenson, Pat Steusloff and Kim T. Rubin in 2002 and is headquartered in San Diego, CA.

PatientSafe Solutions, Inc. provides wireless workflow optimization and patient safety solutions. It designs hardware and software solutions to provide patient safety and improve patient, family, and nurse satisfaction in hospitals. It offers clinical communications and workflows, coordinated care, and professional services. The company was founded by Keith Blei, Gerald E. Forth, David D. Swenson, Pat Steusloff and Kim T. Rubin in 2002 and is headquartered in San Diego, CA.

PatientSafe Solutions, Inc. provides wireless workflow optimization and patient safety solutions. It designs hardware and software solutions to provide patient safety and improve patient, family, and nurse satisfaction in hospitals. It offers clinical communications and workflows, coordinated care, and professional services. The company was founded by Keith Blei, Gerald E. Forth, David D. Swenson, Pat Steusloff and Kim T. Rubin in 2002 and is headquartered in San Diego, CA.

Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA.

Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA.

Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA.